PRIMA BIOMED
Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima‘s lead product is CVac™, an autologous dendritic cell-based product currently in clinical trials for ovarian cancer patients in remission, and soon starting a pilot trial for resected pancreatic cancer. Prima BioMed is listed on the Australian stock exchange, on the NASDAQ in the US and in Germany on the Deutsche Börse in an entry standard.
PRIMA BIOMED
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2001-01-01
Address:
Sydney, New South Wales, Australia
Country:
Australia
Website Url:
http://www.primabiomed.com.au
Total Employee:
11+
Status:
Closed
Contact:
+49 6139 8245254
Email Addresses:
[email protected]
Technology used in webpage:
All-Inkl
Similar Organizations
Fast BioPharma
Fast BioPharma Ltd. develops therapeutic products for treatment of cancer.
Tapestry Pharmaceuticals
Tapestry Pharmaceuticals is a biopharmaceutical company focused on the development of proprietary therapies for the treatment of cancer.
Current Employees Featured
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2014-10-02 | Immutep | Immutep acquired by Prima Biomed | 28 M USD |
Official Site Inspections
http://www.primabiomed.com.au
- Host name: forwarding.syd1.stableserver.net
- IP address: 192.250.232.101
- Location: Las Vegas United States
- Latitude: 36.1682
- Longitude: -115.2166
- Metro Code: 839
- Timezone: America/Los_Angeles
- Postal: 89107
More informations about "Prima Biomed"
Prima BioMed Changes its Name to Immutep Ltd
Nov 20, 2017 About Prima BioMed Prima is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please contact: U.S. Investors: Jay Campbell, …See details»
Prima BioMed Becomes Immutep
Nov 29, 2017 The Company will also trade under the NASDAQ ticker of IMMP. For further information please contact: U.S. Investors: Jay Campbell, Vice President of Business …See details»
Prima BioMed Changes Its Name to Immutep Ltd - GlobeNewswire
Nov 20, 2017 Further shareholder information regarding the change of name can be accessed on the Company’s website www.primabiomed.com.au. About Prima BioMedSee details»
Immutep - Wikipedia
Immutep Ltd (formerly Prima Biomed) is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech. See details»
Prima BioMed Ltd. - Armadale, Australia - bionity.com
11-Aug-2011 | science Novel method for treating ovarian cancer The Fraunhofer Institute for Cell Therapy and Immunology IZI supports the Australian company Prima BioMed Ltd. intests and …See details»
Prima BioMed Announces Strategic Acquisition of Immutep SA
Oct 2, 2014 Prima's lead product is CVacâ„¢, an autologous dendritic cell-based product currently in clinical trials. www.primabiomed.com.au 1 Citi Research, 22 May 2013 - "Immunotherapy - …See details»
Prima BioMed Ltd - VentureRadar
Associated sectors: Major Pharmaceuticals; Pharmaceuticals; Biotechnology; NovaBay Pharmaceuticals NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on …See details»
Prima BioMed Ltd. (PBMD) Starts Presentation at 15th Annual BIO …
Feb 12, 2013 For more information, visit the company’s Web site at www.primabiomed.com.au. The BIO CEO & Investor Conference is the largest investor conference focused on established …See details»
Shareholder Newsletter - SEC.gov
Mr Matthew Lehman Managing Director and Chief Executive Officer Mr Martin Rogers Non-executive Director Dr. Richard Hammel Non-executive Director Senior Management Dr Sharron Gargosky Chief Technical Officer Mr Marc …See details»
Prima Biomed Release: Financial Milestone Payment To Be
Jan 27, 2015 Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value for its shareholders. Following …See details»
EX-99.1 - SEC.gov
Following the acquisition of Immutep SA, Prima owns a number of different immunotherapy products in preclinical and clinical development. www.primabiomed.com.auSee details»
Prima to Present at 2016 Society for Immunotherapy of Cancer …
Oct 13, 2016 Prima BioMed is listed on the Australian Securities Exchange, and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.See details»
Prima BioMed Ltd - Cruelty Free Investing
Our Opinion Prima BioMed Ltd is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical research and therapies.See details»
Prima BioMed to Present at 2nd Annual Cancer Immunotherapy
Jan 23, 2017 Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au. Contact Information:See details»
Prima Biomed (PRR.AX) Appoints New Chief Executive Officer
Jul 11, 2014 Prima's lead product is CVacâ„¢, an autologous dendritic cell-based product currently in clinical trials. www.primabiomed.com.auSee details»
EX-99.1 - SEC.gov
Prima BioMed Ltd , Level 7, 151 Macquarie Street, Sydney NSW 2000 Phone: +61 2 9276 1224 Fax: +61 2 9276 1284 www.primabiomed.com.au ABN: 90 009 237 889 Entities that have …See details»
ARC AWARDS $300,000 TO PANVAX TO DEVELOP FMDV VACCINE.
Aug 1, 2003 Prima Biomed Limited (ASX: PRR) subsidiary Panvax Ltd has received a boost in its vaccine development program with the $300,000 award of an Australian Research Council …See details»
EX-99.1 - SEC.gov
Prima s lead product is CVac , an autologous dendritic cell-based product currently in clinical trials. For further information please contact: USA Investor/Media: Ms. Jessica Brown, Prima …See details»
Prima BioMed's CAN-002 CVac (TM) Trial Published in Journal
Jun 23, 2014 Prima's lead product is CVac an autologous dendritic cell-based product currently in clinical trials. www.primabiomed.com.au Contact Information:See details»
PRIMA BIOMED RECEIVES TGA MANUFACTURING LICENSE FOR …
Prima has now successfully received manufacturing authorisations for CVacTM in in Australia, Europe in October last year (see ASX announcement, 25 October 2011) and is also …See details»